Intercept Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Intercept Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Intercept Pharmaceuticals Inc Strategy Report
- Understand Intercept Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Intercept Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US20220280533A1 | Application | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | A61K31/192; A61K31/216; A61K31/366; A61K31/40; A61K31/451; A61K31/56; A61K31/575; A61K45/06 | September 08, 2022 |
| US20220280534A1 | Application | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | A61K31/192; A61K31/216; A61K31/366; A61K31/40; A61K31/451; A61K31/56; A61K31/575; A61K45/06 | September 08, 2022 |
| IL294575A | Application | Compositions of obeticholic acid and methods of use | A61K31/575; A61K45/06; A61K47/50; A61K9/14; A61K9/1617; A61K9/1652; A61K9/2054; A61K9/2059; A61K9/2072; A61P1/16; A61P31/14; A61P43/00; C07J9/005 | September 01, 2022 |
| US11419878B2 | Grant | Medicine obtained by combining FXR agonist and ARB | A61K31/41; A61K31/4178; A61K31/4184; A61K31/42; A61K31/4245; A61K31/454; A61K31/575; A61K45/06; A61P1/16 | August 23, 2022 |
| US11413295B2 | Grant | Oral preparation of obeticholic acid | A61K31/575; A61K47/10; A61K47/26; A61K47/32; A61K47/36; A61K47/38; A61K9/14; A61K9/1682; A61K9/20; A61K9/28 | August 16, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer